Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Scripps Research is currently prosecuting patents in the Biotechnology & Pharmaceuticals technology area. The organization has 1 pending office action, which is being handled by 1 distinct examiner. This indicates a focused point of activity within its broader research efforts. The involvement of 1 distinct art unit suggests that the pending matter is concentrated in a specific technical field within biotechnology. This lack of complexity in the current workload allows for a concentrated effort on this single pending matter at the USPTO.
The busiest examiner for Scripps Research is WANG, RUIXUE, who is responsible for 1 pending office action. Since there is only 1 pending action in the current data, this examiner is the sole individual reviewing the organization's active applications. The presence of 1 distinct examiner and 1 distinct art unit indicates a very direct prosecution environment. Practitioners should note that the immediate outcome for this specific filing depends entirely on the interaction with this examiner. This streamlined structure ensures that the organization's current patenting resources are focused on a single administrative channel.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WANG, RUIXUE | 1 | 55.9% | +19.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18255612 | REVERSE GENETICS-BASED COMPOSITIONS OF RECOMBINANT SARS-COV-2 | WANG, RUIXUE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18255612 | REVERSE GENETICS-BASED COMPOSITIONS OF RECOMBINANT SARS-COV-2 | WANG, RUIXUE | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18255612 | REVERSE GENETICS-BASED COMPOSITIONS OF RECOMBINANT SARS-COV-2 | WANG, RUIXUE | 1672 | §102§103§112 | Non-Final OA | — | Pending | Jun 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialScripps Research has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ruixue Wang has the most, with 1 of Scripps Research's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
